Abstract: A method of integrating conversational speech into a multimodal, Web-based processing model can include speech recognizing a user spoken utterance directed to a voice-enabled field of a multimodal markup language document presented within a browser. A statistical grammar can be used to determine a recognition result. The method further can include providing the recognition result to the browser, receiving, within a natural language understanding (NLU) system, the recognition result from the browser, and semantically processing the recognition result to determine a meaning. Accordingly, a next programmatic action to be performed can be selected according to the meaning.

Abstract: A coated surface for resisting or enhancing bioadhesion includes at least one patterned polymer including coating layer having a plurality of features attached to or projected into a base surface. The features each have at least one microscale (<1 mm) dimension and have at least one neighboring feature having a substantially different geometry. The patterned coating layer preferably provides an average roughness factor (R) of from 4 to 50. The coating layer resists or enhances bioadhesion as compared to the base surface.

Abstract: A method to facilitate programming of multimodal access in an integrated development environment (IDE). The method can include receiving at least one user input in a view to create a link between a GUI component and a voice component, and correlating the link to a circumstance under which a voice handler is activated. Multimodal markup code that corresponds to the link can be automatically generated.

Abstract: Methods and compositions for prevention and therapy of cancer are provided. Compositions comprising therapeutically effective amounts of two or more of an extract of Ganoderma lucidum, an extract of Salvia miltiorrhiza and an extract of Scutellaria barbata and optionally a therapeutically effective amount of an extract of Hippophae rhamnoides are provided. Novel synergistic effects of the use of these compounds in combination therapy are disclosed. Embodiments further comprising therapeutically effective amounts of at least one chemotherapeutic agent are also provided.

Abstract: A method of accessing an Extensible Hypertext Markup Language Plus Voice Web page can include the step of receiving a request for an Extensible Hypertext Markup Language Plus Voice Web page from a source that lacks the ability to directly render the Web page. The Web page can be segmented into a multitude of fragments, where each fragment can consist of a single interface category, such as a graphical user interface category or a voice category. These fragments can be used to provide the requesting source with information from the Web page.

Abstract: A method for speech enabling an application can include the step of specifying a speech input within a speech-enabled markup. The speech-enabled markup can also specify an application operation that is to be executed responsive to the detection of the speech input. After the speech input has been defined within the speech-enabled markup, the application can be instantiated. The specified speech input can then be detected and the application operation can be responsively executed in accordance with the specified speech-enabled markup.

Abstract: Compounds and compositions for stabilizing microtubules are disclosed. Also disclosed are methods of inhibiting, preventing, regulating, modulating, attenuating, stabilizing, or affecting microtubule formation or function. Methods of treating, preventing or inhibiting diseases and disorders associated with microtubule formation, function, or both by administering a microtubule stabilizing agent such as coumarin is also disclosed.

Abstract: Compounds and compositions for stabilizing microtubules are disclosed. Also disclosed are methods of inhibiting, preventing, regulating, modulating, attenuating, stabilizing, or affecting microtubule formation or function. Methods of treating, preventing or inhibiting diseases and disorders associated with microtubule formation, function, or both by administering a microtubule stabilizing agent such as coumarin is also disclosed.

Abstract: Compounds and compositions for stabilizing microtubules are disclosed. Also disclosed are methods of inhibiting, preventing, regulating, modulating, attenuating, stabilizing, or affecting microtubule formation or function. Methods of treating, preventing or inhibiting diseases and disorders associated with microtubule formation, function, or both by administering a microtubule stabilizing agent such as coumarin is also disclosed.

Abstract: An apparatus in a chemical vapor deposition (CVD) system monitors the actual wafer/substrate temperature during the deposition process. The apparatus makes possible the production of high quality aluminum oxide films with real-time wafer/substrate control. An infrared (IR) temperature monitoring device is used to control the actual wafer temperature to the process temperature setpoint. This eliminates all atmospheric temperature probing. The need for test runs and monitor wafers as well as the resources required to perform the operations is eliminated and operating cost are reduced. High quality, uniform films of aluminum oxide can be deposited on a silicon substrates with no need for additional photolithographic steps to simulate conformality that are present in a sputtered (PVD) type application. The result is a reduction in required process steps with subsequent anticipated savings in equipment, cycle time, chemicals, reduce handling, and increased yield of devices on the substrate.

Abstract: A method and apparatus for monitoring and controlling reactant vapors prior to chemical vapor deposition (CVD). The reactant vapors are monitored at full concentration without sampling as they are transported to a CVD reactor. Contaminants detected cause a process controller to switch the transport path to direct reactant vapors to a system pump.

Abstract: A process and apparatus for Al.sub.2 O.sub.3 CVD on silicon wafers using aluminum tri-isopropoxide in a high-volume production environment is presented. The conditions required to use ATI in a production environment and provide maximum utilization of ATI are first of all delivery of ATI via direct evaporation. The ATI source bottle is pumped out (bypassing substrates) until propene and isopropanol signals are reduced to 1% of process pressure before start of aluminum oxide deposition. Either IR spectroscopy or mass spectrometry can be used to provide a control signal to the microprocessor controller. Heating the supplied tetramer to 120.degree. C. for two hours assures complete conversion to trimer. The ATI is stored at 90.degree. C. to minimize decomposition during idle periods and allow recovery of trimer upon return to 120.degree. C. for two hours. During periods of demand, the ATI is held at 120.degree. C. to minimize decomposition.